Denmark · Delayed Price · Currency is DKK ChemoMetec Statistics
Total Valuation
ChemoMetec has a market cap or net worth of DKK 6.57 billion. The enterprise value is 6.30 billion.
| Market Cap | 6.57B |
| Enterprise Value | 6.30B |
Important Dates
The next confirmed earnings date is Thursday, September 10, 2026.
| Earnings Date | Sep 10, 2026 |
| Ex-Dividend Date | Oct 10, 2025 |
Share Statistics
ChemoMetec has 17.40 million shares outstanding. The number of shares has increased by 0.07% in one year.
| Current Share Class | 17.40M |
| Shares Outstanding | 17.40M |
| Shares Change (YoY) | +0.07% |
| Shares Change (QoQ) | -0.02% |
| Owned by Insiders (%) | 3.78% |
| Owned by Institutions (%) | 33.16% |
| Float | 16.75M |
Valuation Ratios
The trailing PE ratio is 37.13 and the forward PE ratio is 31.49. ChemoMetec's PEG ratio is 3.36.
| PE Ratio | 37.13 |
| Forward PE | 31.49 |
| PS Ratio | 13.33 |
| PB Ratio | 10.07 |
| P/TBV Ratio | 13.56 |
| P/FCF Ratio | 36.66 |
| P/OCF Ratio | 31.28 |
| PEG Ratio | 3.36 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 25.81, with an EV/FCF ratio of 35.16.
| EV / Earnings | 35.60 |
| EV / Sales | 12.78 |
| EV / EBITDA | 25.81 |
| EV / EBIT | 27.27 |
| EV / FCF | 35.16 |
Financial Position
The company has a current ratio of 3.93, with a Debt / Equity ratio of 0.01.
| Current Ratio | 3.93 |
| Quick Ratio | 3.02 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.02 |
| Debt / FCF | 0.03 |
| Interest Coverage | 172.83 |
Financial Efficiency
Return on equity (ROE) is 28.31% and return on invested capital (ROIC) is 46.70%.
| Return on Equity (ROE) | 28.31% |
| Return on Assets (ROA) | 19.08% |
| Return on Invested Capital (ROIC) | 46.70% |
| Return on Capital Employed (ROCE) | 35.01% |
| Weighted Average Cost of Capital (WACC) | 11.60% |
| Revenue Per Employee | 2.87M |
| Profits Per Employee | 1.03M |
| Employee Count | 172 |
| Asset Turnover | 0.65 |
| Inventory Turnover | 0.18 |
Taxes
In the past 12 months, ChemoMetec has paid 51.62 million in taxes.
| Income Tax | 51.62M |
| Effective Tax Rate | 22.58% |
Stock Price Statistics
The stock price has decreased by -25.60% in the last 52 weeks. The beta is 1.34, so ChemoMetec's price volatility has been higher than the market average.
| Beta (5Y) | 1.34 |
| 52-Week Price Change | -25.60% |
| 50-Day Moving Average | 328.71 |
| 200-Day Moving Average | 543.55 |
| Relative Strength Index (RSI) | 62.75 |
| Average Volume (20 Days) | 82,388 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ChemoMetec had revenue of DKK 493.12 million and earned 177.03 million in profits. Earnings per share was 10.17.
| Revenue | 493.12M |
| Gross Profit | 471.14M |
| Operating Income | 231.08M |
| Pretax Income | 228.65M |
| Net Income | 177.03M |
| EBITDA | 244.16M |
| EBIT | 231.08M |
| Earnings Per Share (EPS) | 10.17 |
Balance Sheet
The company has 274.66 million in cash and 5.21 million in debt, with a net cash position of 269.45 million or 15.48 per share.
| Cash & Cash Equivalents | 274.66M |
| Total Debt | 5.21M |
| Net Cash | 269.45M |
| Net Cash Per Share | 15.48 |
| Equity (Book Value) | 652.59M |
| Book Value Per Share | 37.50 |
| Working Capital | 361.17M |
Cash Flow
In the last 12 months, operating cash flow was 210.08 million and capital expenditures -30.85 million, giving a free cash flow of 179.23 million.
| Operating Cash Flow | 210.08M |
| Capital Expenditures | -30.85M |
| Depreciation & Amortization | 13.09M |
| Net Borrowing | 1.52M |
| Free Cash Flow | 179.23M |
| FCF Per Share | 10.30 |
Margins
Gross margin is 95.54%, with operating and profit margins of 46.86% and 35.90%.
| Gross Margin | 95.54% |
| Operating Margin | 46.86% |
| Pretax Margin | 46.37% |
| Profit Margin | 35.90% |
| EBITDA Margin | 49.51% |
| EBIT Margin | 46.86% |
| FCF Margin | 36.35% |
Dividends & Yields
This stock pays an annual dividend of 7.00, which amounts to a dividend yield of 1.85%.
| Dividend Per Share | 7.00 |
| Dividend Yield | 1.85% |
| Dividend Growth (YoY) | 75.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 68.81% |
| Buyback Yield | -0.07% |
| Shareholder Yield | 1.78% |
| Earnings Yield | 2.69% |
| FCF Yield | 2.73% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for ChemoMetec is 546.25, which is 44.66% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 546.25 |
| Price Target Difference | 44.66% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 10.04% |
| EPS Growth Forecast (3Y) | 14.00% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ChemoMetec has an Altman Z-Score of 49.32 and a Piotroski F-Score of 6.
| Altman Z-Score | 49.32 |
| Piotroski F-Score | 6 |